SuperTiny
liked and set a live reminder
Apple Q3 2024 earnings conference call is scheduled for August 1 at 5:00 PM EDT /August 2 at 5:00 AM SGT /August 2 at 7:00 AM AEST. Subscribe to join the live earnings conference with management NOW!
Beat or Miss?
What do you expect from Apple's Q3 earnings? Will the company beat or miss the estimates? Make sure to click the "Book" button to get what management has to say!
Disclaimer:
This presentation is for information and educational use only and is not...
Beat or Miss?
What do you expect from Apple's Q3 earnings? Will the company beat or miss the estimates? Make sure to click the "Book" button to get what management has to say!
Disclaimer:
This presentation is for information and educational use only and is not...
Apple Q3 2024 earnings conference call
Aug 1 16:00
44
8
SuperTiny
liked
35
1
SuperTiny
liked
1
SuperTiny
reacted to
3
SuperTiny
voted
Whales with a lot of money to spend have taken a noticeably bullish stance on $McDonald's (MCD.US)$, Benzinga reported, citing 10 unusual options trades. About 50% of the investors opened trades with bullish expectations and 30% with bearish, it said. Two of them were puts, for a total amount of $111,612 and 8, calls, for a total amount of $344,592.
Trading volumes and open interest data on the contracts traded showed major market movers ...
Trading volumes and open interest data on the contracts traded showed major market movers ...
3
SuperTiny
liked
After years of researches and studies , finally TauRx released the full results and presentation of Phase 3 clinical studies of the flagship medicine named HMTM .
$GENTING (3182.BMS)$ is having a 20% stake in TauRx , in which it is currently not making profits as the principal product HMTM is still under development and yet to be commercialized.
With the data released from the clinical trials , it is likely that TauRx’s HMTM will get the approvals from authority of key...
$GENTING (3182.BMS)$ is having a 20% stake in TauRx , in which it is currently not making profits as the principal product HMTM is still under development and yet to be commercialized.
With the data released from the clinical trials , it is likely that TauRx’s HMTM will get the approvals from authority of key...
93
2